Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy

Acepodia announced that the U.S. Food and Drug Administration has cleared the company’s investigational new drug application for ACE2016, an allogeneic gamma delta 2 T cell therapy for the treatment of epidermal growth factor receptor -expressing malignancies in patients with solid tumors.